Celtrion Healthcare’s Anticancer Biosimilar Products Gain Success in European Market Expansion
Celltrion Healthcare Expands Presence in Major European Countries with Anticancer Biosimilar Products The CEO of Celltrion Healthcare, Kim Hyeong-gi, disclosed that the company is experiencing significant success in the European market with their anticancer biosimilar products. These products have been consistently winning bids in major European countries and are continuously expanding their performance. Biosimilar for […]
Growth in Sales of Celltrion’s Biosimilars Accelerates with New Product Approvals and Increased Demand
Celltrion Healthcare and Celltrion, two major players in autoimmune disease treatments, have secured a supply agreement worth approximately 423.6 billion won. This contract, the largest quarterly supply deal ever, is driven by the increasing demand for antibody biosimilars in the US and Europe, as well as the recent approvals of Humira biosimilars Uplyma and Begzelma. […]
Celltrion and Rani Therapeutics Launch Phase 1 Clinical Trial for Oral Biosimilar
Celltrion Launches Clinical Trials for Oral Ustekinumab Biosimilar Celltrion, under the leadership of CEO Ki Woo-sung, has partnered with Rani Therapeutics to develop an oral biosimilar of ustekinumab, a drug used in the treatment of autoimmune diseases. The biosimilar, named CT-P43 or RT-111, has recently started its phase 1 clinical trials in Australia. Phase 1 […]
Celltrion Applies for Approval of ‘STELARA’ Biosimilar in Australia
Celltrion Applies for Approval of Autoimmune Disease Treatment Biosimilar in Australia The CEO of Celltrion, Ki Woo-seong, has submitted an application for approval of the biosimilar ‘CT-P43’, an item for the treatment of autoimmune diseases, to the Therapeutic Goods Administration (TGA) of Australia. The application, issued on the 31st, encompasses all indications of the originator […]
The Celltrion Group Initiate Merger Process Between Celltrion and Celltrion Healthcare
The merger process between Celltrion and Celltrion Healthcare has been initiated by the Celltrion Group. In a press conference, Celltrion Chairman Seo Jeong-jin announced the plans to merge Celltrion Healthcare and Celltrion within this year, and subsequently merge with Celltrion Pharmaceuticals within six months. The merger of the three Celltrion brothers has generated positive prospects […]
Major Business Updates: Lunit, Kolmar Korea Holdings, Hanmi Pharm·Hanmi Science, The Medipharm, Selma Therapeutics, and Future Medicine
Lunit Announces Paid-Up Capital Increase of KRW 201.9 Billion In a board meeting held on the 23rd, Lunit, a medical AI company, revealed their decision to raise KRW 201.87221 billion through a paid-in capital increase. This move aims to secure funds for operating expenses amounting to KRW 11.14 billion and acquire securities worth KRW 90.792 […]
STGENBIO to Strengthen Global Business Networking with Independent Booth at BIX 2023
STGENBIO to Showcase its Innovations at BIX 2023, Strengthening Global Business Networking SEOUL, Korea – STGENBIO, a subsidiary of Dong-A Socio Holdings, announced its participation in the upcoming BIOPLUS-INTERPHEX KOREA 2023 (BIX 2023) event, set to take place at COEX, Seoul from the 12th to the 14th of this month. BIX 2023, hosted by the […]
